About 80% of early and mid-stage breast cancer patients with two-positive and one-negative breast cancer are likely to survive for more than 10 years. The so-called “two-positive, one-negative” refers to the molecular typing of breast cancer as estrogen receptor and progesterone receptor positive and HER2 (Human Epidermal Growth Factor Receptor 2) negative, which is the type of breast cancer for about 60% of breast cancer patients, and the prognosis of this type of breast cancer is significantly better than that of triple-negative and HER2-positive breast cancers. This type of breast cancer is mainly treated with surgery and postoperative adjuvant endocrine therapy, and radiotherapy may also be needed depending on the stage and surgical method. According to foreign studies with long-term follow-up results, 10-year follow-up data show that the mortality rate (including death from breast cancer and death from non-breast cancer causes) is around 20% in both groups. With the development of individualized treatment, the prognosis of this type of breast cancer is improving. It is recommended to follow the doctor’s instructions to cooperate with the treatment, use the medication on time, and review regularly.